News
Versamune MUC1 is a novel MUC1-targeted immunotherapy designed to target solid tumors overexpressing MUC1, while PDS01ADC is an antibody-drug conjugate aimed at enhancing immune responses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback